Pharmaceuticals, Biotechnology and Life Sciences
The amount that drugmaker Mylan NV avoided paying the U.S. government in Medicaid rebates for its EpiPen emergency allergy treatment since 2007 likely exceeds a proposed $465 million settlement the company announced in October, according to a study by private drug pricing experts published on Monday.
The U.S. Food and Drug Administration has approved Tesaro’s Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.
Novo Nordisk’s new, fast-acting mealtime insulin for the treatment of diabetes in adults, Fiasp has been launched in Canada, following the recent marketing authorisation from Health Canada on 6 January 2017.
Digital Pharmacist Inc., a digital health company, has acquired PocketRx, a mobile app that allows patients to manage their prescriptions.
EMD Serono, U.S. company focused on specialty care has received U.S. Food and Drug Administration (FDA) approval for its rare skin cancer drug.
Latino population in the United States of America have higher rates of cardio-metabolic diseases than in rest of the population, said David Kerr, director of Innovation and Research for the William Sansum Diabetes center.
Three of Europe’s top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi <SASY.PA> and Roche <ROG.S> likely to win approvals for two new products, while GlaxoSmithKline <GSK.L> braces for a potential generic rival.
The U.S. Food and Drug Administration has approved Newron Pharmaceuticals’s Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa.
Steep Hill Labs, a cannabis science and technology company has entered a joint venture with iCAN:Israel-Cannabis to leverage Steep Hill’s science, IP, methodology, global collaboration and brand.
St. Jude Children’s Research Hospital scientists in association with other researchers have worked out how a crucial cancer-related protein, a “histone writer” called Ezh2, plays a role in suppressing as well as driving the most aggressive form of the brain tumor medulloblastoma.